The DOI matches its Crossref record.
Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker
Open accessAbstract
BACKGROUND: Biomarkers to optimize extended adjuvant endocrine therapy for women with estrogen receptor (ER)-positive breast cancer are limited. The HOXB13/IL17BR (H/I) biomarker predicts recurrence risk in ER-positive, lymph node-negative breast cancer patients. H/I was evaluated in MA.17 trial for prognostic performance for late recurrence and treatment benefit from extended adjuvant letrozole. METHODS: A prospective-retrospective, nested case-control design of 83 recurrences matched to 166 nonrecurrences from letrozole- and placebo-treated patients within MA.17 was conducted. Expression of H/I within primary tumors was determined by reverse-transcription polymerase chain reaction with a prespecified cutpoint. The predictive ability of H/I for ascertaining benefit from letrozole was determined using multivariable conditional logistic regression including standard clinicopathological factors as covariates. All statistical tests were two-sided. RESULTS: High H/I was statistically significantly associated with a decrease in late recurrence in patients receiving extended letrozole therapy (odds ratio [OR] = 0.35; 95% confidence interval [CI] = 0.16 to 0.75; P = .007). In an adjusted model with standard clinicopathological factors, high H/I remained statistically significantly associated with patient benefit from letrozole (OR = 0.33; 95% CI = 0.15 to 0.73; P = .006). Reduction in the absolute risk of recurrence at 5 years was 16.5% for patients with high H/I (P = .007). The interaction between H/I and letrozole treatment was statistically significant (P = .03). CONCLUSIONS: In the absence of extended letrozole therapy, high H/I identifies a subgroup of ER-positive patients disease-free after 5 years of tamoxifen who are at risk for late recurrence. When extended endocrine therapy with letrozole is prescribed, high H/I predicts benefit from therapy and a decreased probability of late disease recurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Duffy, M. J., Harbeck, N., Nap, M., Molina, R., Nicolini, A., Senkus, E., & Cardoso, F. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.017 · Cited by 522
Spring, L. M., Gupta, A., Reynolds, K. L., Gadd, M. A., Ellisen, L. W., Isakoff, S. J., Moy, B., & Bardia, A. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1897 · Cited by 396
Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer
Zhang, X. H.-F., Giuliano, M., Trivedi, M. V., Schiff, R., & Osborne, C. K. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0838 · Cited by 264
Metadata
- Authors
- Sgroi, D. C., Carney, E., Zarrella, E., Steffel, L., Binns, S. N., Finkelstein, D. M., Szymonifka, J., Bhan, A. K., Shepherd, L. E., Zhang, Y., Schnabel, C. A., Erlander, M. G., Ingle, J. N., Porter, P., Muss, H. B., Pritchard, K. I., Tu, D., Rimm, D. L., & Goss, P. E.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-07-13
- Volume
- 105
- Issue
- 14
- Pages
- 1036-1042
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2159216027
- Cited by
- 229
- References
- 0
- FWCI
- 4.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker. https://app.cochat.ai/papers/10.1093/jnci/djt146
- The paper
- Sgroi, D. C., Carney, E., Zarrella, E., Steffel, L., Binns, S. N., Finkelstein, D. M., Szymonifka, J., Bhan, A. K., Shepherd, L. E., Zhang, Y., Schnabel, C. A., Erlander, M. G., Ingle, J. N., Porter, P., Muss, H. B., Pritchard, K. I., Tu, D., Rimm, D. L., & Goss, P. E. (2013). Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djt146
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
